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Introduction
Well-conducted biomedical research tells us how best to act
in various clinical situations. In order to do so, ethical and legal rules
have been developed over time for optimal study conduct, with spe-
cial attention to the subjects involved in these studies. This includes
asking informed consent before including a person in a clinical trial,
and protection of fragile and mentally incompetent individuals by re-
stricting and regulating their participation in biomedical research.
Apart from the obvious positive effects, these regulations may
also lead to unintended restrictions, and as a result not all relevant
patient subgroups are sufficiently included in human clinical re-
search. Consequently, important questions on how to optimally
treat certain patient groups remain unanswered.
The objective of this ‘current opinion’ article is to explore how
therapeutic scientific research and procedures can be better
exploited, to advance clinical expertise and to discuss ethical issues
that need to be considered in that context. For that purpose, we
reflect on the challenges and consequences of patient selection,
studies in acute care setting, and comparison of established therap-
ies, in the final part illustrated by discussing some relevant recent
clinical trials.
We all appreciate the fact that biomedical research in humans
should be guided by high ethical standards, as outlined in the Dec-
laration of Helsinki,1 among which informed consent of the subject
before participation in a trial. Nevertheless, we propose that, in or-
der to obtain optimal scientific and clinical data, certain study types
should not require (pre-study) informed consent, while still guaran-
teeing patients essential (ethical) rights and safety.
Historical context of ethics
in clinical trials
Current Good Clinical Practice rules are strict and defensive, and
often demand labour-intensive procedures. This was partly a re-
sponse to unethical human experiments in the past. Since
A. Neisser performed syphilis experiments in 1892 without inform-
ing participants that they were enrolled in an experiment,2 ethical
standards have developed, but have also been overstretched on
multiple occasions. Excesses demanded adaptation of prevailing
rules, culminating in the Nuremberg Doctors’ Trial in 1947. In add-
ition to it being a trial of the horrible medical experimental crimes
that had been committed during World War II, it subsequently re-
sulted in the Code of Nuremberg. This Code defined the 10 most
important conditions to which future biomedical research with hu-
mans should comply, among which that it is only justified after vol-
untary consent for participation from the study subject.2 TheWorld
Medical Association formulated norms and values on biomedical re-
search in humans in the Declaration of Helsinki in 1964.1
The Declaration of Helsinki used to distinguish therapeutic and
non-therapeutic scientific research.1 Research in which the subject
may personally benefit from the intervention is considered thera-
peutic, for instance when two approved therapies are compared.
If informed consent is deemed appropriate, but a person is unable
to communicate, a proxy can give consent, in the interest of the
patient. A study is regarded as non-therapeutic if no health-related
direct benefit for a specific patient is anticipated, for example
when physiological processes are evaluated. Participants of non-
therapeutic studies should give informed consent. In principle, a
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proxy never has the right to take decisions for an incompetent pa-
tient concerning non-therapeutic research, as this is not in the direct
interest of the patient.
Challenges arise
When trying to comply with all rules and guidelines on conducting
biomedical research in humans, several challenges may be faced. For
instance, obtaining informed consent of the persons involved can be
difficult, due to the age or the mental status of the patients or with
severely ill patients who are unable to communicate. Parents give
consent for treatment of their children and a proxy decides on be-
half of a patient with intellectual disabilities. Moreover, if patients are
in need of acute clinical interventions, it may not be feasible to dis-
cuss the type of treatments and a randomization procedure. This
may lead to underrepresentation of such patient groups in clinical
trials. Since these patients may form a substantial part of the patient
population in daily practice and are particularly prone to a bad out-
come, there may be a serious gap between knowledge obtained in
clinical trial populations and knowledge needed for the optimal
acute treatment in daily clinical practice.
Trial populations vs. the real world:
neglected patient groups
Not all patients who might later be eligible to receive a given treat-
ment are included in studies needed for approval of that treatment.
Exclusion criteria in clinical trials serve to yield a homogeneous
study population; a first step towards obtaining robust results and
registration by regulators (European Medicines Authority, Food
and Drug Administration). Patients with multimorbidity and/or poly-
pharmacy are often excluded from clinical trials. Even if for instance
elderly patients are included, they may not adequately reflect the
target population; trial participants often are in better condition
than most people of that age group who visit the clinic in daily prac-
tice. Moreover, patients participating in clinical trials may have bet-
ter clinical outcome than those not enrolled in trials, as a result of
better care provided in trial settings. This strongly limits the gener-
alizability of the study results.3,4 Fortunately, some research teams
acknowledged this data hiatus and have conducted studies to exam-
ine treatment of these previously neglected patient groups. Import-
ant insights have been obtained in the Hypertension in the Very
Elderly Trial5 and the ‘Pravastatin in elderly individuals at risk of
vascular disease’ trial.6
Patient registries with follow-up data can form another valuable
source of real-world information without including patients in clin-
ical trials. Registries may suffer from some inclusion confounding
bias. Even if certain clinicians or clinical centres have non-evidence-
based preferences for one therapy over another, retrospective
comparisons of therapeutic approaches are possible and may be hy-
pothesis generating, as long as treatment decisions and outcomes
are properly documented. Registry-based comparative studies are
certainly valuable, but can never substitute randomized trials and
cannot (timely) provide all information that is currently required
in clinical practice.
We propose to place the often rigid division between scientific
research and patient care in perspective. Especially in academic hos-
pitals, patient care should be accompanied by critical review and
analysis of medical practice and its outcomes. In that context, it
should be practically feasible and considered acceptable to do
head-to-head comparisons of two approved treatments without
prior patient consent in case of clinical equipoise, and with similar
guideline recommendations. Note that patients should still give con-
sent for the overall treatment strategy. Obviously, the research pro-
cess may not pose patients at extra risk of harm. This approach can
solve the current situation that certain patient groups are neglected
in clinical research.
More and easier to conduct
prospective randomized trials
may be the answer
In addition to registry-based evaluation of therapies, we are in favour
of conducting prospective randomized trials. Different randomiza-
tion protocols can be considered for which informed consent
may not always be necessary. Treatment options may be rando-
mized according to time or to medical centre location. In certain
conditions, individual patients may even be randomized to different
treatment options consecutively, which means that they can
serve as their own control. There is only one crucial condition:
full transparency for patients and other citizens about a combined
treatment-research policy. To this extent, academic health centres
may emphasize more clearly that research is part of the care pro-
cess, including that an individual patient may participate in a research
protocol and not be informed until later, provided of course no
extra risk of harm is imposed.
In order to keep data storage, randomization, and follow-up af-
fordable and feasible, online (national) systematic registries may
play an important role in the future. Scandinavia is taking the lead
with, for example, the Thrombus Aspiration in ST-Elevation myo-
cardial infarction (STEMI) in Scandinavia (TASTE) trial. This was a
multicentre, prospective, randomized, controlled trial that benefit-
ted from the Swedish Coronary Angiography and Angioplasty
Registry to blindly evaluate clinical endpoints in STEMI patients
randomized to either conventional percutaneous coronary inter-
vention (PCI) or to thrombus aspiration followed by PCI.7 Techno-
logical developments should be exploited to facilitate better and
safe use of anonymized patient data.
For most investigators, the process of randomization is synonym-
ous to the obligation to ask patients for informed consent. How-
ever, informed consent may not always be needed in case of a
therapeutic study, in which benefit is anticipated for every individual
patient. Patients may for example be randomized to one of several
already approved therapies, especially when they are of similar
nature and have similar guideline recommendations. Of course,
patients will always be carefully evaluated beforehand to ensure
that they are suitable for either intervention. Without the intended
study, it remains unknown which treatment is objectively the best
and treatment choices are based on subjective judgement. Seen
from a patient’s perspective, he/she will receive either one of
two treatment options somewhat randomly—depending on the
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doctor’s preferences. In order to get rid of this uncontrollable
(doctor’s) bias, it would be better to formally randomize this pa-
tient. No informed consent is necessary, since no investigation-
related discomfort or risk is expected for the patient. But once
again: full transparency is a crucial prerequisite.
Moreover, certain (therapeutic) research questions concern ur-
gent situations, in which patients or a proxy is unable to take a well-
considered decision. After approval of an ethical review committee,
this type of research in which randomization takes place before con-
sent has been obtained, is allowed in urgent care settings. Informed
consent to use the clinical data for research purposes can be ob-
tained when the patient is stabilized. Neonatologists conduct stud-
ies in this context, for instance to evaluate ventilation conditions in
(premature) newborns. Obviously, an obligatory condition for de-
layed consent is that the research can only be conducted in urgent
settings (trauma, neonatal unit, myocardial infarction, and stroke).
Thus, randomization does not automatically imply the obligation
to obtain informed consent. Rather what is the alternative for pa-
tients who would refuse to give consent? Will their treatment be al-
tered? No. Will they receive alternative treatment? No. The only,
clearly non-desirable effect is that data of non-included patients
will not be used, and that the lessons thereof will not become avail-
able to other clinicians and the patients themselves in the future.
In the last part of this article, we will try to illustrate the above-
mentioned points by discussing (recent) clinical trials
Prospectively randomized
procedures without prior informed
consent: unethical or
ground-breaking? A heated debate
Already in the 1990s, the GISSI trials evaluating the effect of intra-
venous thrombolytic therapy in acute myocardial infarction did
not obtain informed consent before randomization. Based on the
GISSI and other trials, Tognoni argued that ‘the view that informed
consent is the most important component of the “ethical” aspects
of experimentation is highly misleading’.8 The GISSI trials gave more
weight to communication than to consent, by informing the patient
about his/her inclusion in the trial only once the physician consid-
ered it not to be emotionally damaging. The approach focussed
on protection of the ‘right of the patient not to be exposed to an
emotionally burdensome request for informed consent’. The design
was approved after considerable ethical review.8
Another, more recent illustrative example of a prospective ran-
domized trial was the ‘how effective are antithrombotic therapies
in primary percutaneous coronary intervention’ (HEAT-PPCI) trial.
It was unknown which of two approved and commonly used (with
similar guideline recommendations) types of adjunctive antithrom-
botic therapy was best for patients presenting with acute STEMI
with an indication to undergo PPCI. Thus, HEAT-PPCI randomized
consecutive adults scheduled for angiography in the context of
PPCI.9 A delayed consent strategy was followed: patients were ran-
domly allocated to periprocedural bivalirudin or unfractionated
heparin before undergoing angiography and no attempt was made
in this emergency setting to discuss the trial or obtain consent.
Surviving patients or their proxies were approached for formal con-
sent to proceed as trial participants, and to use their data and par-
ticipate in the 28-day follow-up. This procedure received full ethical
approval because two crucial conditions were met: equipoise ther-
apies and acute setting. Furthermore, the national Confidentiality
Advisory Group granted approval to include clinical data and out-
comemeasures of patients who died after randomization but before
consent could be obtained.
This pragmatic therapeutic study design, in which approved med-
ical interventions for this specific indication were applied, was cho-
sen to specifically address a common limitation of randomized
clinical trials, namely to recruit only part of the potential, eligible
population and in particular thosewith a more favourable prognosis.
This precludes medical progress for those in greatest need. To im-
prove the generalizability of the study results, they aimed to include
every eligible patient entering the catheterization lab for PPCI. This
way, also very sick, elderly, or frail patients, or those with low socio-
economic status or from ethnic minorities were included; indivi-
duals who are rarely approached for participation in clinical studies.
Only four of the 1917 trial participants refused or withdrew their
delayed consent, indicating that patients generally agreed with the
procedure.9 Similarly, most parents give consent for neonatal re-
search after their infants have been enrolled in an acute setting in
the delivery room.10
Despite in our opinion praiseworthy aim and study design, and
despite the approval of three separate ethical review committees,
HEAT-PPCI raised a heated debate when it was presented at the
American College of Cardiology 2014 Scientific Sessions. Received
with a hostile attitude by some, and considered positively ground-
breaking by others, HEAT-PPCI has sparked an important discus-
sion. In an editorial comment in The Lancet,11 David Shaw wrote
that the chosen delayed consent strategy may even have been too
conservative. Shaw argues ‘Consent might not be necessary in
some pragmatic comparative effectiveness trials. Despite the trad-
ition of obtaining informed consent for almost all research, some de-
bate surrounds whether patient consent should be sought when
both treatments are licensed, consensus is present regarding equi-
poise, and randomization does not pose any added risk. Outcome
data can be used without consent in normal clinical care and audit,
and randomization alone does not make consent necessary’.11
Practical solutions: transparency
and ‘de-juridification’
Rigid application of guidelines on obtaining informed consent may
prove counterproductive by limiting the number and representa-
tiveness of included patients in a study. Transparency can solve
some of the dilemma’s surrounding randomization and informed
consent. Hospitals have no reason to hide that they perform this
kind of studies. On the contrary, this research approach should be
appreciated in the context of the obligation of (academic) medical
centres not only to provide optimal care but also to monitor quality
of care and to advance clinical expertise. As stated in Article 6 of the
Declaration of Helsinki: ‘Even the best proven interventions must be
evaluated continually through research for their safety, effective-
ness, efficiency, accessibility and quality’.1 Special attention and
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explanation about the options should be given to fragile patient
groups. Choosing not to ‘bother’ elderly patients with procedures
sometimes deemed complicated, maintains the situation in which
it is not known how to best treat these patients.
Hence, we advocate a ‘de-juridification’ of the information pro-
cess between a clinician/researcher and a patient. A clinician should
reasonably inform patients. At the same time, a patient should ac-
cept that a doctor can propose treatment strategies to his/her
best judgement, as long as, to the best of our knowledge, no harm
is done to the patient, or the healing process is not delayed. If the
treatment to be tested concerns approved similar interventions, it
should NOT be necessary to ask patients for consent for the re-
search aspect (see Figure 1). This is a legitimate means to gather clin-
ical experience and insights, and transparency about this type of
research contributes to its legitimation. If treatment options have
not been approved, informed consent of the patient or a proxy is
always needed.
Patients should be aware that they themselves benefit from such
learning processes. It is crucial in a healthy society that patients trust
their doctors, implying that patients should have some confidence
that their doctors are to be trusted. A important role is also played
by health organizations and medical institutes, in that they are re-
sponsible for creating circumstances that ensure ethical behaviour.
In non-therapeutic study settings, if the study subject does not
directly benefit from the intervention, obtaining informed consent
is obligatory (see Figure 1). At a practical level, comprehensive
patient consent forms can greatly facilitate these processes. These
important documents should be readable and contain only a few
(1 or 2) pages, rather than a.20 pages long version resembling legal
documents that merely deal with shirking liabilities.
Conclusion
We strongly believe that under certain conditions prospective ran-
domized trials can be conducted without asking consent. Of course,
adequate trial size and conduct are paramount to obtaining high-
quality information. This will facilitate filling gaps in the evidence
on treatment of commonly neglected patient groups, by better re-
presenting the daily practice population that will receive the ther-
apy. Simplicity and transparency will likely increase the willingness
of patients to participate in studies.
We should learn from experience and benefit from clinical data if
they were obtained in the general process of providing care. We
therefore propose to use a simple paradigm: unless it is clearly un-
feasible to do so, when in doubt about the best treatment: random-
ize with a proper procedure that is as simple as possible and in line
with high medical ethical standards!
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